Synovial tissue response to treatment in psoriatic arthritis
- PMID: 22279513
- PMCID: PMC3263446
- DOI: 10.2174/1874312901105010133
Synovial tissue response to treatment in psoriatic arthritis
Abstract
Following its validation and wide application in rheumatoid arthritis (RA), synovial tissue analysis has recently been applied to studies on Psoriatic Arthritis (PsA). Such studies aim to thereby clarify its distinctive features and the nature of specific responses upon administration of disease modifying anti-rheumatic drug (DMARD) or biologic agents. In consequence, insights to disease pathogenesis, drugs' mechanisms of action (MOA) and biomarkers of response have emerged. Data from pilot and open-label studies, and recently from randomized controlled trials, have helped in refining the therapeutic approaches to PsA patients, by improving understanding of MOA and in provision of biomarkers of response. The availability of less invasive and reproducible analysis techniques to obtain and evaluate synovial biopsies will further enhance the utility of this approach in due course.
Keywords: Biologic therapy; biomarker; psoriatic arthritis; synovial tissue,.
Similar articles
-
Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis.Arthritis Res Ther. 2019 May 9;21(1):116. doi: 10.1186/s13075-019-1898-7. Arthritis Res Ther. 2019. PMID: 31072400 Free PMC article.
-
[Psoriatic synovitis: pathogenic and therapeutic implications].Reumatol Clin. 2005 Dec;1(4):218-22. doi: 10.1016/S1699-258X(05)72747-9. Epub 2008 Dec 20. Reumatol Clin. 2005. PMID: 21794267 Spanish.
-
Synovial Immunohistological Biomarkers of the Classification of Undifferentiated Arthritis Evolving to Rheumatoid or Psoriatic Arthritis.Front Med (Lausanne). 2021 Apr 9;8:656667. doi: 10.3389/fmed.2021.656667. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33898490 Free PMC article.
-
Apremilast and its role in psoriatic arthritis.G Ital Dermatol Venereol. 2020 Aug;155(4):386-399. doi: 10.23736/S0392-0488.20.06640-7. G Ital Dermatol Venereol. 2020. PMID: 33050680 Review.
-
TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.BioDrugs. 2005;19(1):47-57. doi: 10.2165/00063030-200519010-00006. BioDrugs. 2005. PMID: 15691217 Review.
Cited by
-
Profile of certolizumab and its potential in the treatment of psoriatic arthritis.Drug Des Devel Ther. 2013 Apr 15;7:339-48. doi: 10.2147/DDDT.S31658. Print 2013. Drug Des Devel Ther. 2013. PMID: 23620660 Free PMC article. Review.
-
Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.Cochrane Database Syst Rev. 2025 Feb 13;2(2):CD013614. doi: 10.1002/14651858.CD013614.pub2. Cochrane Database Syst Rev. 2025. PMID: 39945386
-
From Bed to Bench and Back: TNF-α, IL-23/IL-17A, and JAK-Dependent Inflammation in the Pathogenesis of Psoriatic Synovitis.Front Pharmacol. 2021 Jun 15;12:672515. doi: 10.3389/fphar.2021.672515. eCollection 2021. Front Pharmacol. 2021. PMID: 34211394 Free PMC article. Review.
References
-
- Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73. - PubMed
-
- Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997;40:1868–72. - PubMed
-
- Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol. 2008;26:S62–5. - PubMed
-
- Bresnihan B, Baeten D, Firestein GS, et al. Synovial tissue analysis in clinical trials. J Rheumatol. 2005;32:2481–4. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous